AstraZeneca has dropped 6 drug programs from its pipeline--with almost all the early-stage candidates being axed from its MedImmune biologics arms--in what is…

In this week's EuroBiotech Report, Genmab, J&J bag a breakthrough designation, Merck dumps ALK, uniQure yo-yos on gene therapy data and more.

BioMarin Pharmaceutical gained almost $1 billion in market cap on strong positive data for its gene therapy to treat severe hemophilia A.

Specialty pharma InnoPharma was acquired by Pfizer a few years ago for up to $360 million. Now, the team behind that effort is at it again with another…

Unlikely IPO candidate Kadmon made it out in a tough IPO market amid swirling criticisms of its rather infamous current and former management, namely the…

Building on the original 2013 R&D deal between Japan’s Astellas and Cytokinetics, the two have now expanded their initial collab, which will see Astellas…

The tau theory in Alzheimer’s disease took a hit today after TauRx, one of the leading companies researching this hypothesis, saw its drug when used with…

Merck has shocked ALK-Abello by returning the rights to three sublingual allergy immunotherapy tablets, triggered an 18% drop in the Danish firm's share…